Valuation: Samil Pharmaceutical Co.,Ltd

Market Cap 147B 101M 88.56M 82.36M 75.57M 142M 9.71B 144M 978M 382M 4.77B 379M 370M 16.51B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 313M 214K 188K 175K 161K 302K 20.66M 307K 2.08M 813K 10.16M 805K 788K 35.11M EV / Sales 2026 *
1.33x
EV / Sales 2027 * 1.2x
Free-Float
71.77%
Yield 2026 *
-
Yield 2027 * -
1 day+4.39%
1 week+11.49%
Current month+4.39%
1 month+15.41%
3 months-28.15%
6 months-27.78%
Current year-28.90%
1 week 5,800
Extreme 5800
8,100
1 month 5,500
Extreme 5500
8,100
Current year 5,500
Extreme 5500
12,860
1 year 5,500
Extreme 5500
12,860
3 years 5,500
Extreme 5500
19,500
5 years 5,500
Extreme 5500
19,500
10 years 3,154.55
Extreme 3154.5455
29,000
Manager TitleAgeSince
Chief Executive Officer 61 2017-12-31
Chief Executive Officer 45 -
Corporate Officer/Principal 53 2023-03-23
Director TitleAgeSince
Chairman 45 -
Director/Board Member 61 2012-12-31
Director/Board Member 62 2020-03-19
Date Insider Type Main position Quantity % Market Cap.
5/15/25 Buy

Director

599 0.0028%
5/15/25 Buy

Director

1,200 0.0055%
5/15/25 Buy

Director

772 0.0036%
Change 5-day change 1-year change 3-year change Capi.($)
+4.39%+11.49%-35.00%+5.35% 101M
-0.66%+0.44%+14.25%+74.56% 48.36B
-0.54%-0.18%+57.77%+106.69% 35.8B
+1.26%-0.57%-7.95%+32.02% 11.83B
-0.46%-3.06%+13.55%+78.03% 11.48B
-0.37%-0.37%+37.53%+142.08% 9.01B
-0.53%+0.96%+46.22%-9.16% 6.99B
-0.17%-2.92%+11.72%+31.34% 6.7B
-0.59%-1.95%+2.18%+171.86% 6.42B
-7.92%-13.61%-33.87%-3.30% 5.3B
Average -0.60%-0.31%+10.64%+62.95% 14.2B
Weighted average by Cap. -0.75%-0.44%+23.87%+78.97%

Financials

2026 *2027 *
Net sales 235B 161M 141M 131M 121M 227M 15.5B 230M 1.56B 610M 7.62B 604M 591M 26.34B 267B 183M 161M 149M 137M 257M 17.61B 261M 1.77B 693M 8.66B 686M 672M 29.93B
Net income - -
Net Debt 166B 114M 99.84M 92.85M 85.2M 160M 10.95B 163M 1.1B 431M 5.38B 427M 418M 18.61B 174B 119M 105M 97.32M 89.3M 168M 11.47B 170M 1.16B 452M 5.64B 447M 438M 19.5B
Logo Samil Pharmaceutical Co.,Ltd
Samil Pharmaceutical Co Ltd is a Korean-based company primarily engaged in the manufacturing and sale of pharmaceuticals. The Company operates through two segments. The Pharmaceutical segment mainly manufactures gastrointestinal motility regulators, nutritional supplements, gastrointestinal treatments, antipyretic analgesics and anti-inflammatory drugs, liver disease treatments and antihistamines, and also sells products used for glaucoma, depression and dry eyes. The Other segment mainly provides related services and also provides rental services. The Company also engages in the development of new drugs for ophthalmic diseases, liver diseases and circulatory and musculoskeletal conditions.
Employees
583
Date Price Change Volume
26-07-24 ₩6,890.00 +4.39% 1,024,224
26-07-23 ₩6,600.00 +5.26% 96,507
26-07-22 ₩6,270.00 +0.64% 78,004
26-07-21 ₩6,230.00 +4.88% 126,785
Trader
-
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6,890.00KRW
Average target price
10,000.00KRW
Spread / Average Target
+45.14%

Net sales - Rate of surprise

  1. Stock Market
  2. Stocks
  3. A000520 Stock